Skip to main content
永顺生物 logo

永顺生物 — Investor Relations & Filings

Ticker · 920729 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 388 across all filing types
Latest filing 2025-04-27 Board/Management Inform…
Country CN China
Listing Beijing Stock Exchange 920729

About 永顺生物

https://www.winsun-gd.com/

Guangdong Winsun Bio-Pharmaceutical Co., Ltd. is a specialized enterprise focused on the research, development, production, and distribution of veterinary biological products. The company primarily develops vaccines for livestock and poultry, with a significant emphasis on swine and avian health. Its product portfolio includes live and inactivated vaccines targeting major diseases such as classical swine fever, porcine reproductive and respiratory syndrome (PRRS), and avian influenza. Winsun Bio-Pharmaceutical leverages advanced biotechnology to provide comprehensive animal disease prevention and control solutions. The company maintains a strong focus on technological innovation and quality management, operating multiple GMP-certified production lines to ensure the efficacy and safety of its biological preparations. Its research initiatives often involve collaborations with academic institutions to advance veterinary medicine and support the animal husbandry sector.

Recent filings

Filing Released Lang Actions
董事会关于独立董事独立性自查情况的专项报告
Board/Management Information Classification · 95% confidence The document is a special report from the board of directors regarding the independence of the company's independent directors. It references regulatory requirements from the China Securities Regulatory Commission and the Beijing Stock Exchange, and it evaluates the independence criteria of the independent directors. The content is focused on governance and compliance with independence rules rather than financial results or other report types. The document length is short (945 characters), and it is a standalone report on board/management information related to director independence. Therefore, it fits best under Board/Management Information (MANG).
2025-04-27 Chinese
2024年度独立董事述职报告（任涛）
Board/Management Information Classification · 95% confidence The document is titled '2024年度独立董事述职报告（任涛）' which translates to '2024 Annual Independent Director's Work Report (Ren Tao)'. It is a detailed report by an independent director about their duties, attendance, communication with audit institutions, and protection of investors' rights during the year 2024. The content focuses on the director's activities, compliance with laws, attendance at meetings, and oversight responsibilities. It is not an announcement of voting results, not a financial report like an annual or interim report, nor a regulatory filing or certification. It is a management-related report focusing on board/management information, specifically the independent director's report on their duties and activities. Given the nature and content, the best fitting category is Board/Management Information (MANG). The document length is 2580 characters, which is relatively short but contains substantive content about management activities, not just an announcement or certification. Therefore, classification as MANG is appropriate with high confidence.
2025-04-27 Chinese
会计政策变更公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding a change in accounting policies by Guangdong Yongshun Biopharmaceutical Co., Ltd. It details the nature of the accounting policy changes, the reasons for the changes, and the approvals by the board, audit committee, and supervisory board. The document does not contain full financial statements or detailed financial performance data but rather focuses on the policy change announcement and related governance approvals. The document length is short (1645 characters), and it serves as a formal announcement of the accounting policy change rather than a full report or audit report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-04-27 Chinese
董事辞职公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the resignation of a company director, Mr. Chen Shaoyang, from the board of Guangdong Yongshun Biopharmaceutical Co., Ltd. It details the resignation date, reasons, and the impact on the company's board composition and operations. There is no financial data, no mention of financial results, reports, or regulatory filings beyond the resignation notice. This fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management.
2025-04-27 Chinese
关于预计2025年日常性关联交易的公告
Board/Management Information Classification · 95% confidence The document is an announcement regarding the expected related party transactions for the year 2025 by Guangdong Yongshun Biopharmaceutical Co., Ltd. It details the nature, amounts, counterparties, and approvals related to these transactions. It includes information on board and supervisory committee approvals and voting results related to these transactions. The document does not contain financial statements or comprehensive financial data but rather focuses on governance and management decisions about related party transactions. This fits best under Board/Management Information (MANG), which covers announcements of changes or decisions by the company's board or senior management, including related party transaction approvals.
2025-04-27 Chinese
关于向银行申请授信额度的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Guangdong Yongshun Biopharmaceutical Co., Ltd. regarding its application for credit facilities from multiple banks totaling 600 million RMB. It details the credit application, the board meeting resolutions approving the credit proposals, and the necessity and impact of the credit on the company. There are no financial statements, earnings data, or detailed financial analysis present. The document is a formal announcement about financing activities, specifically about applying for bank credit lines. This fits the definition of a Capital/Financing Update (CAP) filing, which covers updates on company fundraising and financing activities. The document length is short (1211 characters), and it is not merely announcing the publication of a report but is itself the announcement of financing activity. Therefore, the correct classification is CAP with high confidence.
2025-04-27 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.